Treatment of leuprolide-induced depression with intramuscular testosterone: A case report [6]

Journal of Clinical Psychiatry

Volumn 64, Issue 3, 2003, Pages 341-343

  Freeman, Marlene P ^a   Freeman, Scott A ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; GONADORELIN; LEUPRORELIN; LORAZEPAM; SERTRALINE; TESTOSTERONE;

AGED; AMNESIA; ANHEDONIA; ANXIETY DISORDER; APPETITE DISORDER; CANCER RISK; CASE REPORT; CLINICAL FEATURE; DEPRESSION; FATIGUE; HOT FLUSH; HUMAN; HYPOGONADISM; LETTER; LIBIDO DISORDER; MALE; MANIA; MOOD DISORDER; MUSCLE WEAKNESS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SIDE EFFECT; SLEEP DISORDER; TESTOSTERONE BLOOD LEVEL; TREATMENT FAILURE;

EID: 0037365754     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0317h     Document Type: Letter

References (16)

1. Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord 1998;48:157-161
2. Rabkin JG, Rabkin R, Wagner G. Testosterone replacement therapy in HIV illness. Gen Hosp Psychiatry 1995;17:37-42
3. Palinkas LA, Barrett-Conner E. Estrogen use and depressive symptoms in postmenopausal women. Obstet Gynecol 1992;80:30-36
4. Rosenblatt DE. Mellow A. Depression during hormonal treatment of prostate cancer. J Am Board Fam Pract 1995:8:317-320
5. Rachman M, Garfield DAS. Rachman I, et al. Lupron-induced mania. Biol Psychiatry 1999;45:243-244
6. Warnock JK, Bundren JC. Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy. Psychopharmacol Bull 1997;33:311-316
7. Lupron [package insert]. Deerfield, III: TAP Pharmaceuticals; 1995
8. Zoladex [package insert]. Wilmington, Del: Zeneca Pharmaceuticals; 1995
9. Barrera CM, Kastin AJ, Fasold MB. et al. Bidirectional saturable transport of LHRH across the blood-brain barrier. Am J Physiol 1991;261:E312-E318
10. Seidman SN, Spatz E, Rizzo C, et al. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J Clin Psychiatry 2001;62:406-412
11. Nejat RJ, Rashid HH, Bagiella E, et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 2000;164:1891-1894
12. Seidman SN, Araujo AB, Roose SP, et al. Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. Biol Psychiatry 2001;50:371-376
13. Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 2000;57:133-140
14. Basaria S, Dobs AS. Risks versus benefits of testosterone therapy in elderly men. Drugs Aging 1999;15:131-142
15. Rolf C, Nieschlag E. Potential adverse effects of long-term testosterone therapy. Baillieres Clin Endocrinol Metab 1998;12:521-534
16. Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 2000;5:162-168